Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Good morning, everyone. Damian here with the latest twist for a futuristic cancer therapy, big money for longevity research, and a dispatch from London.
The need-to-know this morning
• Karuna Therapeutics said its application seeking the approval of a new treatment for schizophrenia was accepted by the Food and Drug Administration. The agency will review the drug, called KarXT, and render a decision on or before Sept. 26, 2024. Karuna has conducted two successful Phase 3 clinical trials showing KarXT reduced psychosis in people with schizophrenia.
Continue to STAT+ to read the full story…